- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03223740
Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy (President)
A Phase III Trial of Preoperative or Postoperative Chemoradiation Therapy for Potentially Resectable Adenocarcinoma of Stomach Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Qian Peng, MD PhD
- Phone Number: 008617708130617
- Email: pengqian0522@163.com
Study Locations
-
-
Shanxi
-
Xi'an, Shanxi, China, 710032
- Active, not recruiting
- Xijing Hospital, GI institute
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Recruiting
- friendship Hospital
-
Contact:
- lili deng, MD
- Phone Number: +8613880926676
-
Siyang, Sichuan, China
- Recruiting
- Ziyang People's Hospital
-
Contact:
- min wei, MD
- Phone Number: +8613980386078
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with potentially resectable adenocarcinoma of the stomach with histologic proof.
- EUS or MRI stage T3-4, any N, M0.
- Adequate bone marrow (defined as peripheral absolute granulocyte count of > 2,000/μL, and platelet count of>100,000/μL), liver (bilirubin < 1.5 mg/dl), and renal functions (creatinine < 1.5 mg/dl).
- Absence of peritoneal disease by laparoscopic staging; no positive cytology of pleural, or pericardial effusion.
- No prior major surgery or radiotherapy to the stomach, or immunotherapy or chemotherapy for any reason.
- Patients must have a life expectancy of at least 16 weeks.
- Performance status of < 2 (Zubrod scale).
- No biopsy proof of lymph node metastases outside the study field.
- No evidence of metastatic disease to distant organs.
- No presence of concurrent or previous malignancies < 5 years, other than noninvasive skin cancer.
- No uncontrolled or severe cardiac disease, diabetes or hypertension.
- Signed study-specific consent form prior to study entry.
Exclusion Criteria:
- Evidence of metastatic disease
- Prior chemotherapy or radiotherapy
- Patients with a past history of cancer
- Patients with other significant underlying medical conditions that may be aggravated by the study treatment or are not controlled
- Pregnant or lactating females or female patients of childbearing potential who have not been surgically sterilized or are without adequate contraceptive measures
- Cardiac failure or Sever Pulmonary disease
- Patients with impaired gastrointestinal absorption for whatever reason
- Patients medically unfit for cisplatin or taxol chemotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 pre-operative chemoradiation
Chemo1 x 2 followed by ChemRT followed by Surgery followed by Chemo2 x 2
|
Chemotherapy 1: First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5. Chemoradiotherapy: At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks. Chemotherapy2: Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition. 2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29. |
Active Comparator: Arm 2 post operative chemoradiation
Surgery followed by Chemo1 x 2 followed by ChemRT followed by Chemo2 x 2
|
Surgical resection, a D2 resection is encouraged. Chemotherapy 1: All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22. Chemoradiotherapy: At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks. Chemotherapy2: 2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29 |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression Free Survival
Time Frame: up to 5 year
|
up to 5 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival
Time Frame: up to 5 year
|
up to 5 year
|
R0 Resection Rate
Time Frame: At time of surgery
|
At time of surgery
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Ming Zeng, MD PhD, Sichuan Academy of Medical Science
- Study Chair: Hongwei Zhang, MD PhD, Xijing Hosptial, GI institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- President Trial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Gastric Carcinoma
-
Astellas Pharma Global Development, Inc.AvailableMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma CancerUnited States
-
Yang Jianjun, PhDRecruitingLocally Advanced Gastric AdenocarcinomaChina
-
Xijing HospitalRecruitingLocally Advanced Gastric AdenocarcinomaChina
-
Tianjin Medical University Cancer Institute and...RecruitingLocally Advanced Gastric AdenocarcinomaChina
-
Xijing HospitalRecruitingPD-1 | Locally Advanced Gastric AdenocarcinomaChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage... and other conditions
-
FutureGen Biopharmaceutical (Beijing) Co., LtdRecruitingLocally Advanced Unresectable or Metastatic Gastric Cancer | Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaChina
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Clinical Trials on Arm 1 pre-operative chemoradiation
-
Medical University of South CarolinaCompletedGrowth Failure | Congenital Heart DefectsUnited States
-
The First Affiliated Hospital of Guangzhou Medical...UnknownNon-small Cell Lung CancerChina
-
University of VirginiaAmerican Cancer Society, Inc.; Integrated Translational Health Research Institute...RecruitingBladder Cancer | Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
Methodist University, North CarolinaCape Fear Orthopedics & Sports MedicineNot yet recruitingDistal Radius Fracture | Thumb Osteoarthritis | Flexor Tendon Rupture
-
University of Michigan Rogel Cancer CenterRecruitingOropharyngeal Cancer | Squamous Cell Carcinoma of the OropharynxUnited States
-
Rambam Health Care CampusCompleted
-
Linkoeping UniversityRegion Östergötland; Region Jönköping CountyRecruitingKnee OsteoarthritisSweden
-
University of California, DavisRecruitingAnxiety | SurgeryUnited States
-
University College London HospitalsCompletedAppendicitisUnited Kingdom